GlassScriptPhysician profile
John F Dunn
NPI 1164733937
$18,790.72
in general payments reported to CMS, 2019-2025
37 companies · $3,675 in 2025
The $3,675 reported for 2025 was more than what 87% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,807 · 2020: $1,237 · 2021: $2,124 · 2022: $3,290 · 2023: $3,454 · 2024: $3,204 · 2025: $3,675.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Education: $89.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,242.73 |
| Education | $89.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,631.45 | 2019-2025 | Skyrizi, Rinvoq |
| Janssen Biotech, INC. | $2,019.93 | 2019-2025 | Tremfya, Simponi, Simponi Aria |
| Novartis Pharmaceuticals Corporation | $1,987.99 | 2019-2025 | |
| Lilly USA, LLC | $1,523.83 | 2019-2025 | Taltz, Olumiant, Ebglyss |
| Regeneron Healthcare Solutions, INC. | $1,348.15 | 2019-2025 | Dupixent |
| Ucb, INC. | $1,029.27 | 2019-2025 | Bimzelx, Cimzia |
| Sun Pharmaceutical Industries INC. | $962.08 | 2019-2025 | Winlevi, Absorica Ld, Ilumya |
| Galderma Laboratories, L.P. | $838.60 | 2019-2025 | Nemluvio, Aklief |
| Pfizer INC. | $736.41 | 2020-2025 | |
| E.R. Squibb & Sons, L.L.C. | $715.79 | 2021-2025 | Sotyktu |
| Amgen INC. | $614.58 | 2019-2025 | Otezla, Otezla |
| Arcutis Biotherapeutics, INC. | $558.01 | 2023-2025 | Zoryve |
| Genzyme Corporation | $506.75 | 2021-2025 | |
| Incyte Corporation | $366.74 | 2021-2025 | Opzelura |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $322.63 | 2019-2025 | Jublia, Arazlo, Cabtreo |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $312.55 | 2019-2025 | Adbry, Anzupgo |
| Epi Health, LLC | $290.80 | 2019-2022 | |
| Regeneron Pharmaceuticals, INC. | $248.71 | 2019-2025 | Dupixent |
| Revance Therapeutics, INC. | $168.72 | 2024-2025 | Daxxify |
| Janssen Scientific Affairs, LLC | $96.24 | 2019-2020 | |
| Mayne Pharma Commercial LLC | $77.87 | 2020-2023 | |
| Almirall LLC | $64.24 | 2019-2023 | Klisyri |
| Merz North America, INC. | $57.10 | 2019-2023 | Xeomin |
| Celgene Corporation | $50.23 | 2019 | |
| Dermavant Sciences, INC. | $41.07 | 2023 | Vtama |
| Vyne Pharmaceuticals INC. | $37.17 | 2020-2021 | |
| Dermira, INC. | $21.61 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.36 | 2022 | |
| Encore Dermatology INC. | $18.73 | 2019 | |
| Tempus Ai, INC | $18.60 | 2024 | Merlin Test |
| Medimetriks Pharmaceuticals, INC. | $18.57 | 2019 | |
| Verrica Pharmaceuticals INC. | $16.12 | 2024 | Ycanth |
| Sebela Pharmaceuticals INC. | $15.21 | 2021 | |
| Journey Medical Corporation | $15.02 | 2023 | |
| Solta Medical, A Division of Bausch Health US, LLC | $14.88 | 2022 | |
| Hill Dermaceuticals, INC. | $13.34 | 2021 | |
| Organon LLC | $11.37 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Dunn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.